Get the Stockscreener App
8.6635
0.87%
0.0535
Biocryst Pharmaceuticals Inc stock is traded at $8.6635, with a volume of 2.17M.
It is up +0.87% in the last 24 hours and up +13.98% over the past month.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
See More
Previous Close:
$8.61
Open:
$8.58
24h Volume:
2.17M
Relative Volume:
0.86
Market Cap:
$1.79B
Revenue:
$331.41M
Net Income/Loss:
$-226.54M
P/E Ratio:
-7.3419
EPS:
-1.18
Net Cash Flow:
$-97.31M
1W Performance:
+4.76%
1M Performance:
+13.98%
6M Performance:
+5.27%
1Y Performance:
+54.54%
1-Day Range:
$8.49
$8.80
1-Week Range:
$7.935
$8.80
52-Week Range:
$4.03
$9.50
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Name
Biocryst Pharmaceuticals Inc
Sector
Phone
919-859-1302
Address
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
8.66 | 1.79B | 331.41M | -226.54M | -97.31M | -1.18 |
|
ZTS
Zoetis Inc
|
168.74 | 75.15B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.62 | 47.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.96 | 47.70B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.20 | 18.75B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.30 | 13.96B | 612.78M | -86.37M | -62.91M | -0.87 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-25 | Initiated | Wedbush | Outperform |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Sep-18-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-04-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-13-23 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-22-23 | Upgrade | Needham | Hold → Buy |
| Nov-02-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-05-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-05-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-18-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Aug-06-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-03-21 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Sep-29-20 | Resumed | JP Morgan | Overweight |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| May-05-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-15-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| May-24-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-16-18 | Resumed | Piper Jaffray | Overweight |
| Aug-08-18 | Resumed | JP Morgan | Overweight |
| Jul-17-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jun-22-18 | Initiated | Seaport Global Securities | Neutral |
| Jan-02-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-20-17 | Initiated | Barclays | Equal Weight |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-06-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-17 | Upgrade | Jefferies | Hold → Buy |
| Feb-16-17 | Initiated | Ladenburg Thalmann | Buy |
| Aug-12-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-04-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-09-16 | Reiterated | FBR Capital | Outperform |
| Feb-09-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-09-16 | Downgrade | Needham | Buy → Hold |
View All
Biocryst Pharmaceuticals Inc Stock (BCRX) Latest News
BioCryst stock holds $18 target, JMP bullish on trial results By Investing.com - Investing.com Canada
Is BioCryst Pharmaceuticals, Inc. (BCRX) the Best Small-Cap Stock to Buy Now? - Insider Monkey
Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher - MSN
BioCryst Pharmaceuticals' (BCRX) "Outperform" Rating Reaffirmed at Royal Bank of Canada - MarketBeat
Wedbush Initiates Coverage on BioCryst Pharmaceuticals (NASDAQ:BCRX) - MarketBeat
HC Wainwright Reiterates Buy Rating for BioCryst Pharmaceuticals (NASDAQ:BCRX) - MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) Issues Earnings Results - MarketBeat
BioCryst stock soars to 52-week high, touches $9.02 - MSN
BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Analysts Set Expectations for BCRX Q1 Earnings - MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down Following Weak Earnings - MarketBeat
Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know - MSN
BioCryst: ORLADEYO's Expansion Is Just Getting Started (NASDAQ:BCRX) - Seeking Alpha
BioCryst: Hold Steady As Orladeyo Builds, But Competition Heats Up (NASDAQ:BCRX) - Seeking Alpha
BioCryst Pharmaceuticals' SWOT analysis: strong orladeyo sales drive stock outlook By Investing.com - Investing.com South Africa
BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical - Seeking Alpha
BioCryst Pharmaceuticals' SWOT analysis: stock outlook amid Orladeyo growth, pipeline shifts - Investing.com Canada
BioCryst Pharmaceuticals’ SWOT analysis: stock outlook amid Orladeyo growth, pipeline shifts - Investing.com
BioCryst Pharmaceuticals' SWOT analysis: stock outlook amid Orladeyo growth, pipeline shifts By Investing.com - Investing.com South Africa
Wedbush bullish on BioCryst, initiates with an Outperform - TipRanks
Earnings call transcript: BioCryst Pharmaceuticals Q4 2024 misses EPS forecast - Investing.com Australia
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2024 Earnings Call Transcript - Insider Monkey
BioCryst Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
BioCryst Pharmaceuticals Inc (BCRX) Q4 2024 Earnings Call Highlights: Strong ORLADEYO Revenue ... - Yahoo Finance
BioCryst Pharmaceuticals Inc (BCRX) Q4 2024 Earnings Call Highlights: Strong ORLADEYO Revenue ... By GuruFocus - Investing.com Canada
BioCryst Pharmaceuticals' SWOT analysis: strong orladeyo sales drive stock outlook - Investing.com India
BioCryst Pharmaceuticals’ SWOT analysis: strong orladeyo sales drive stock outlook - Investing.com
Earnings call transcript: BioCryst Pharmaceuticals Q4 2024 misses EPS forecast By Investing.com - Investing.com South Africa
BioCryst Pharmaceuticals Reports Strong 2024 Revenue Growth - TipRanks
Piper Sandler maintains BioCryst stock Overweight with $23 target By Investing.com - Investing.com Canada
Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today - MSN
BioCryst (BCRX) Stock Drops on Earnings and Mixed Guidance - GuruFocus.com
Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today - The Motley Fool
BioCryst Breaks Barriers: Record-Breaking Growth and a Bold Future in 2025 - Jomfruland.net
BioCryst Pharmaceuticals (BCRX) Q4 2024 Earnings Call Transcript - Yahoo
Piper Sandler maintains BioCryst stock Overweight with $23 target - Investing.com India
BioCryst Faces Patent Challenge Amidst Strong Growth - TipRanks
BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings - Benzinga
BioCryst stock drops following Q4 earnings miss By Investing.com - Investing.com South Africa
JPMorgan maintains BioCryst stock with $10 target, upbeat on growth By Investing.com - Investing.com South Africa
BioCryst stock drops following Q4 earnings miss - Investing.com
JPMorgan maintains BioCryst stock with $10 target, upbeat on growth - Investing.com
BioCryst: Q4 Earnings Snapshot - CTPost
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
BioCryst Pharmaceuticals Q4 2024 Earnings: Revenue Surpasses Est - GuruFocus.com
BIOCRYST PHARMACEUTICALS Earnings Results: $BCRX Reports Quarterly Earnings - Nasdaq
BioCryst Pharma Reports Positive Data From APeX-P Study In Hereditary Angioedema - Nasdaq
BioCryst: Q4 Earnings Snapshot -February 24, 2025 at 07:18 am EST - Marketscreener.com
Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q4 Revenue $131.5M, vs. FactSet Est of $130.1M - Marketscreener.com
Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q4 Loss $-0.13 Per Share, vs. FactSet Est of $-0.06 - Marketscreener.com
BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones - The Bakersfield Californian
Biocryst Pharmaceuticals Inc Stock (BCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
1.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):